Skip to content
Akums Drugs & Pharma logo

Akums Drugs & Pharma

Akums Drugs & Pharmaceuticals Ltd

AKUMS NSE
₹751.50 −9.65 (−1.27%)
P/E
40.56
View as Markdown
MCP
Close 4 Nov 2026 ₹751.50 +291.15 +63.2% 1Y
Start ₹460.35

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
14.90%
Debt to Equity
0.05
EPS (TTM)
₹18.53
Book Value
₹222.61
Market Cap
—
P/E (TTM)
40.56
P/B
3.38
ROE
8.45%
Dividend Yield
0.39%
EBITDA
₹651 Cr
52W High
₹838.80
52W Low
₹409.30
Day Range
₹729.40 – ₹774.05
Volume
3,72,268

Peer Comparison

Healthcare › Pharmaceuticals

Akums Drugs & Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Akums Drugs & Pharma (this company)
₹751.5040.56₹11,537 Cr3.380.39%8.45%14.90%₹4,502 Cr₹293 Cr
Median 8 companies₹1,587.7039.69₹1,25,337 Cr4.570.49%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

54 Average

Data confidence 100/100

Category scores

Quality
49
Average
Returns, margins, earnings quality 22% weight
Valuation
70
Strong
Cheap vs sector & own history 24% weight
Growth
32
Poor
Sales & profit trajectory 9% weight
Financial Health
45
Weak
Solvency, leverage, coverage 9% weight
Momentum
67
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

3
  • Stock is trading at 3.47 times its book value
  • The company has delivered a poor sales growth of 9.87% over past five years.
  • Company has a low return on equity of 9.89% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2512
OscillatorsBullish153
Moving AveragesStrong Bullish109

Key readings

RSI (14)
51.86
Neutral
MACD (12,26,9)
−8.61
Bullish
SMA (50)
764.48
Bearish
SMA (200)
607.37
Bullish

As of

Analyst Rating

Based on 3 analysts
BUY100%

3 of 3 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
3
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+10.20%
5Y+9.87%
3Y+6.05%
1Y+5.85%
TTM+9.22%

Net profit

Net profit growth by window
10Y+15.42%
5Y+15.79%
3Y+37.72%
1Y−25.58%
TTM−15.80%

Operating cash flow

Operating cash flow growth by window
10Y+29.50%
5Y+55.24%
3Y+88.26%
1Y+153.98%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+3.26 pp
5Y+3.24 pp
3Y+3.94 pp
1Y+0.69 pp
TTM+1.33 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2015₹1,464 Cr
Mar 2016₹1,651 Cr
Mar 2020₹2,414 Cr
Mar 2021₹2,723 Cr
Mar 2022₹3,672 Cr
Mar 2023₹3,655 Cr
Mar 2024₹4,178 Cr
Mar 2025₹4,118 Cr
Mar 2026₹4,359 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2015₹43.00 Cr
Mar 2016₹61.00 Cr
Mar 2020₹44.00 Cr
Mar 2021₹123 Cr
Mar 2022−₹251 Cr
Mar 2023₹98.00 Cr
Mar 2024₹1.00 Cr
Mar 2025₹344 Cr
Mar 2026₹256 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹729 Cr +12.1% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk medium

Akums Drugs & Pharmaceuticals trades at a market cap of ₹9,883 Cr with a PE of 38.4x and is nearly debt-free. However, recent TTM profit growth has turned negative at -14% and ROE remains modest at 8-10%, presenting a mixed picture for a healthcare CDMO player at this valuation.

Bull Case 7
  • Company is almost debt-free, providing significant financial flexibility and low interest burden in a capital-intensive pharma sector
  • Compounded profit growth of 29% over 3 years demonstrates strong earnings trajectory over the medium term
  • Long-term compounded sales growth of 10% over both 5-year and 10-year periods shows consistent revenue expansion
  • Compounded profit growth of 16% over both 5-year and 10-year horizons indicates sustainable long-term earnings compounding
  • Dividend yield of 0.48% provides some income return, uncommon among growth-stage pharma companies
  • Stock has delivered 8% CAGR over 1 year, indicating positive price momentum despite broader market volatility
  • CDMO business model in India's growing pharmaceutical outsourcing market benefits from structural industry tailwinds with 10% long-term sales CAGR as evidence
Bear Case 8
  • PE ratio of 38.4x is elevated for a company delivering only 6% TTM sales growth, suggesting stretched valuations
  • TTM compounded profit growth has turned negative at -14%, indicating recent earnings deterioration
  • Return on equity of just 9.72% over last 3 years is low for a company trading at 2.98x book value
  • Recent sales growth has decelerated to 6% TTM from the 10% five-year CAGR, signaling a slowdown
  • Price-to-book ratio of 2.97x is high relative to the modest 8% ROE delivered in the last year
  • 5-year sales CAGR of 9.87% is considered poor growth for a mid-cap pharma company at premium valuations
  • ROE has declined from 10% (3-year average) to 8% in the last year, showing deteriorating capital efficiency
  • 5-year ROE average of only 6% suggests the company historically struggles to generate adequate returns on shareholder equity

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Akums is maintaining steady shareholder engagement through investor conferences and a ₹3 per share dividend announcement. No material headwinds surfaced in the recent news cycle. The company's proactive ESG reporting and capital return signal stable governance. Near-term catalysts depend on AGM approval of the dividend on July 10 and any strategic updates from investor interactions.

Positives 1
  • ₹3 dividend record date set Jun 16

    Akums fixed July 3, 2026 as record date for a final and special dividend of ₹3 per share, subject to shareholder approval at the AGM on July 10.

Neutral 2
  • BRSR FY26 ESG report filed Jun 18

    Akums filed its Business Responsibility and Sustainability Report for FY 2025-26 detailing energy consumption, waste management, and employee welfare metrics.

  • Investor meets in June Jun 10

    Akums scheduled investor meetings in Singapore and Mumbai on June 15, and hosted the InsightX 2026 Virtual Conference on June 12 at 12:00 noon IST. No unpublished price sensitive information shared.

Quarterly Results

₹ Cr
AKUMS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
970
1,181
1,083
944
1,019
1,033
1,010
1,056
1,024
1,018
1,160
1,158
1,167
1,342
Expenses
1,095
1,029
989
941
891
912
889
962
895
923
1,013
1,006
992
1,148
Operating Profit
−125
152
93
3
128
121
121
94
129
94
147
152
175
195
OPM %
−13%
13%
9%
0.3%
13%
12%
12%
9%
13%
9%
13%
13%
15%
15%
Other Income
8
−21
10
10
7
17
19
26
27
32
16
34
30
29
Interest
12
14
12
12
13
12
5
5
23
23
24
24
25
26
Depreciation
30
30
32
34
34
35
45
40
37
38
40
40
41
43
PBT
−159
87
59
−33
87
92
91
75
96
66
100
121
139
155
Tax %
18%
62%
−229%
20%
30%
27%
27%
−99%
32%
35%
32%
33%
27%
26%
Net Profit
−187
33
195
−39
61
67
66
150
65
43
68
81
101
115
EPS (₹)
−13.16
2.22
13.54
−2.89
4.08
4.14
4.14
9.38
4.03
2.59
4.21
5.38
6.35
—

Sep 2026: from the results filed on 2 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
AKUMS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,464
1,651
2,414
2,723
3,672
3,655
4,178
4,118
4,359
4,502
Expenses
1,340
1,507
2,240
2,485
3,761
3,361
4,055
3,654
3,837
3,934
Operating Profit
124
144
174
238
−89
294
123
465
522
568
OPM %
8%
9%
7%
9%
−2.4%
8%
3%
11%
12%
13%
Other Income
6
6
26
11
7
15
8
69
108
112
Interest
23
22
20
7
17
46
51
35
94
96
Depreciation
31
38
67
70
95
113
126
153
155
159
PBT
77
89
114
172
−193
150
−45
345
382
426
Tax %
51%
50%
62%
28%
30%
35%
−102%
0%
33%
—
Net Profit
43
61
44
123
−251
98
1
344
256
293
EPS (₹)
3.32
4.74
3.05
8.58
−17.65
6.63
−0.28
21.49
16.21
18.53
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
18%
—

Balance Sheet

₹ Cr
AKUMS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1
1
1
1
14
29
29
31
31
Reserves
493
628
721
884
608
689
681
3,016
3,283
Borrowings
255
213
175
130
395
619
565
88
157
Other Liabilities
293
318
1,140
1,137
2,033
1,905
2,229
960
1,958
Total Liabilities
1,042
1,161
2,037
2,152
3,050
3,241
3,504
4,095
5,429
Fixed Assets
444
501
645
904
1,021
1,097
1,191
1,397
1,456
CWIP
0
11
57
17
31
103
195
163
177
Investments
0
18
6
20
0
0
0
0
0
Other Assets
598
632
1,329
1,212
1,998
2,041
2,118
2,535
3,796
Total Assets
1,042
1,161
2,037
2,152
3,050
3,241
3,504
4,095
5,429

Cash Flow

₹ Cr
AKUMS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
72
89
28
131
32
177
498
465
1,181
Investing
−150
−123
−190
−109
−235
−305
−331
−548
−930
Financing
66
37
233
−91
236
125
−108
73
34
Net Cash Flow
−11
4
71
−70
33
−4
59
−10
285
Free Cash Flow
−78
−34
−34
49
−224
−110
212
201
958
CFO/EBITDA
72
98
44
74
−98
93
455
118
243

Ratios

AKUMS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
57
88
71
88
84
73
68
67
Inventory Days
114
115
99
93
112
117
90
102
110
Days Payable
67
60
105
74
92
91
76
96
87
Cash Conversion Cycle
115
112
82
90
109
111
87
74
89
Working Capital Days
78
73
55
66
49
46
40
71
66
ROCE %
—
14%
—
20%
−16%
22%
2%
16%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Akums Drugs & Pharma insights

67 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 75.26%
  • DIIs 11.08%
  • Public 6.43%
  • FIIs 4.50%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Akums Drugs & Pharma

What does Akums Drugs & Pharmaceuticals Ltd do?
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.
Where is Akums Drugs & Pharmaceuticals Ltd (AKUMS) listed?
Akums Drugs & Pharmaceuticals Ltd trades as AKUMS on the NSE and under code 544222 on the BSE.
Which sector does Akums Drugs & Pharmaceuticals Ltd belong to?
Akums Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd trades at a PE ratio of 40.56 as of 4 Nov 2026, on earnings per share of ₹18.53, against a book value of ₹222.61 per share.
What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Akums Drugs & Pharmaceuticals Ltd has traded between ₹409.3 and ₹838.8 as of 4 Nov 2026.
Does Akums Drugs & Pharmaceuticals Ltd pay dividends?
Akums Drugs & Pharmaceuticals Ltd has a dividend yield of 0.39%.
What is the Return on Equity (ROE) of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd reported a return on equity of 8.45%. Its debt-to-equity ratio is 0.05.

Company Information

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.

Website akums.in
CEO Mr. Sanjeev Jain
Employees 7,536
Listed 6 Aug 2024
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AKUMS.md for Akums Drugs & Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month